U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468136) titled 'Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas' on March 09.
Brief Summary: This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse (progressive). Immunotherapy with monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. DFMO is in a class of medications called ornithine decarboxylase (ODC) inhibitor...